Obesity Drug Developer BioAge Makes Nasdaq Debut

Image Source:  via Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead obesity drug further into clinical trials.

Latest IPOs and Direct Listings
BioAge () opened on Sept. 26 at $22.50. The clinical-stage biopharmaceutical company, which develops therapeutic product candidates for metabolic diseases such as obesity by targeting the biology of aging, had priced its upsized initial public offering of 11 million shares at a public offering price of $18.00 per share.Innovation Beverage Group () opened on Sept. 26 at $3. The company had priced in 1.35 million shares at $4.00. The deal size was reduced to 1.35 million shares from 1.40 million. Innovation Beverage is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands with a focus on premium and super premium brands whose products are sold in both the United States and Australian markets.BKV Corp. () opened on Sept. 26 at $18.55. The company had priced in 15 million shares at $18.00. The deal was priced below the $19.00-$21.00 target range. BKV Corp. is a Denver-based Barnett Shale natural-gas producer.Guardian Pharmacy () opened on Sept. 26 at $14.46. The company had priced its upsized initial public offering of 8 million shares of Class A common stock at a public offering price of $14.00 per share. Guardian is a long-term care pharmacy services company that provides a suite of technology-enabled services designed to help residents of long-term health care facilities, or “LTCFs,” adhere to their appropriate drug regimen. As of June 30, 2024, its 50 pharmacies served approximately 174,000 residents in approximately 6,700 LTCFs across 36 states.Legacy Education () opened on Sept. 26 at $4. The for-profit post-secondary education company, which offers a range of education programs and services to help students achieve their professional goals, priced its initial public offering of 2.5 million shares of common stock at a price to the public of $4.00 per share.Global Engine () opened on Sept. 20 at $5.15. The Hong Kong-headquartered integrated solutions provider in information communication technologies had priced its initial public offering of 2 million shares at a public offering price of $4.00 per share.

Recent SPAC IPOs
Cayson Acquisition () opened on Sept. 20 at $10. The blank check company intends to focus its search for a target business on entities located throughout Asia, but says it “will not be limited to a particular industry or geographic location.”YHN Acquisition I () opened on Sept. 18 at $10.01. The blank check company said its efforts to identify a prospective target business will not be limited to a particular industry or geographic location.

End-of-the-Week Performance

  • BioAge closed the week at $21.
  • Innovation Beverage Group closed the week at $2.53.
  • BKV Corp. closed the week at $18.05.
  • Guardian Pharmacy closed the week at $17.75.
  • Legacy Education closed the week at $4.39.
  • Global Engine closed the week at $4.55.
  • Recent IPOs to Watch
    Pheton Holdings () and Powell Max () are among stocks that could see new coverage roll out this upcoming week as the quiet periods for banks that underwrote the companies’ IPOs expire.

    Upcoming IPOs
    Upcoming IPO and direct listings expected include the likes of BingEx, Upstream Bio, Basel Medical Group, Megan Holdings, Health In Tech, Leizig Thermal Management, and ShipBob.BingEx Limited filed for an initial public offering of American depositary shares, or ADSs, via which it will be offering 4 million shares to be sold in the offering. Each ADS represents three of its Class A ordinary shares. The company anticipates that the initial public offering price will be between $15.00 and $17.00 per ADS. The prospectus filed with the SEC states the following: 

    “We are the largest independent on-demand dedicated courier service provider in China as measured by revenue in 2023, according to iResearch. Since the inception of our commercial operation in 2014, our business has flourished with individual and business customers embracing the on-demand dedicated courier industry. As of June 30, 2024, we had approximately 2.7 million registered riders, and had expanded our services coverage to 295 cities in China. In 2023, our market share of the independent on-demand dedicated courier service in China was approximately 33.9%, according to iResearch.”

    Upstream Bio has filed for an initial public offering of shares of its common stock. The prospectus filed with the SEC stated:

     “We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin, or ‘TSLP,’ a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.

    “Preclinical and clinical data to date demonstrate verekitug’s highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of patients.

    “We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plan to initiate development in chronic obstructive pulmonary disease, or ‘COPD’… Verekitug is, to our knowledge, the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor.”

    Basel Medical Group filed for an initial public offering on the Nasdaq under the symbol “BMGL.” Cathay Securities is serving as the underwriter on the deal. Basel is a healthcare provider across Singapore and Southeast Asia.Megan Holdings filed with the SEC for an initial public offering of 1.25 million ordinary shares of Megan Holdings Limited, a Cayman Islands exempted company, which is being conducted on a firm commitment basis.”We expect that the offering price of our Ordinary Shares in this offering will be between US$4.00 and US$6.00 per share. Prior to this offering, there has been no public market for our Ordinary Shares. We have applied to list our Ordinary Shares on the Nasdaq Capital Market under the symbol ‘MGN’,” the filing stated.Health In Tech has filed with the SEC for a firm commitment initial public offering of shares of Class A Common Stock and anticipates that the initial public offering price of its shares will be between $4.00 and $5.00 per share. Its prospectus states:

    “Health in Tech is an insurance technology platform company, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs.”

    Leizig Thermal Management has filed for an initial public offering, on a firm commitment basis, of 1,875,000 ordinary shares based on an assumed public offering price of $5.00, the mid-point of the range expected. Based in the People’s Republic of China, Leizig is a manufacturer of enclosure climate controls, with a focus on industrial cabinet ventilation, refrigeration, dehumidification, heat exchange, heating, lighting, and environmental monitors.MNTN, the connected TV advertising platform operator whose Chief Creative Officer is Hollywood star Ryan Reynolds, has selected Morgan Stanley () to work on an initial public offering and is considering going public as soon as in early 2025, people familiar with the matter told ‘s Bailey Lipschultz and Gillian Tan.MNTN, which acquired Reynolds’ creative agency Maximum Effort in 2021, raised $119 million in a Series D financing round in 2021 co-led by funds and accounts managed by BlackRock () and Fidelity Management, which together invested about $110 million, the report noted.ShipBob has selected JPMorgan () to lead its planned listing, Bloomberg’s Amy Or, Gillian Tan, and Ryan Gould  earlier this year, citing people familiar with the situation. The Chicago-based e-commerce fulfillment service provider has also chosen Citigroup () as part of the syndicate, the authors said. An initial public offering could occur as soon as later this year and could value the company at $4 billion, the authors noted.More By This Author:Wall Street’s Top 10 Stock Calls This Week – Saturday, Sept. 28Wall Street More Bullish On Meta AI Following Connect Event Here’s What Wall Street Is Saying About Micron Ahead Of Earnings

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    This site uses Akismet to reduce spam. Learn how your comment data is processed.